ObjectivesAfter subtotal colectomy, 40% of patients report chronic gastrointestinal symptoms and poor quality of life. Its etiology is unknown. We determined whether small intestinal bacterial overgrowth (SIBO) or small intestinal fungal overgrowth (SIFO) cause gastrointestinal symptoms after colectomy.MethodsConsecutive patients with unexplained abdominal pain, gas, bloating and diarrhea (>1 year), and without colectomy (controls), and with colectomy were evaluated with symptom questionnaires, glucose breath test (GBT) and/or duodenal aspiration/culture. Baseline symptoms, prevalence of SIBO/SIFO, and response to treatment were compared between groups.ResultsFifty patients with colectomy and 50 controls were evaluated. A significantly higher (p = 0.005) proportion of patients with colectomy, 31/50 (62%) had SIBO compared to controls 16/50 (32%). Patients with colectomy had significantly higher (p = 0.017) prevalence of mixed SIBO/SIFO 12/50 (24%) compared to controls 4/50 (8%). SIFO prevalence was higher in colectomy but not significant (p = 0.08). There was higher prevalence of aerobic organisms together with decreased anaerobic and mixed organisms in the colectomy group compared to controls (p = 0.008). Patients with colectomy reported significantly greater severity of diarrhea (p = 0.029), vomiting (p < 0.001), and abdominal pain (p = 0.05) compared to controls, at baseline. After antibiotics, 74% of patients with SIBO/SIFO in the colectomy and 69% in the control group improved (p = 0.69).ConclusionPatients with colectomy demonstrate significantly higher prevalence of SIBO/SIFO and greater severity of gastrointestinal symptoms. Colectomy is a risk factor for SIBO/SIFO.
INTRODUCTION:
Upper gastrointestinal bleeding (UGIB) is one of the most common GIemergencies, which frequently requires hospitalization. This condition accounts for 400,000 hospital admissions per year and costs more than $2 billion annually. The purpose of our study was to identify risk factors associated with prolonged hospital stay in non-variceal UGIB patients.
METHODS:
We conducted a retrospective study through an electronic medical record review of patients admitted at University Medical Center, Lubbock, Texas between January 2012 and December 2015. Patients older than 18 years with UGIB identified by the ICD-9 diagnosis code 578.9 (hemorrhage of gastrointestinal tract, unspecified) were enrolled into the study. Admissions were excluded if patients did not undergo EGD or if they had documented underlying cirrhosis. Statistical Package for Social Sciences (SPSS™) version 22 was used for statistical analysis.
RESULTS:
143 patients met inclusion criteria. 83 were men (58.0%), 92 were Caucasian (64.3%), 33 were Hispanic (22.4%), and the mean age was 60.9 + 17.1 years. 33% of patients requiring FFP transfusion underwent endoscopic therapy. The mean length of stay (LOS) was significantly increased in patients requiring endoscopic therapy, FFP transfusion, and inthose who had underwent EGD after 24 hours. LOS was also significantly increased in patients that presented with acute kidney injury (AKI) or hypoalbuminemia. There was no correlation between prolonged hospital stay and Glasgow-Blatchford bleeding score, pre-endoscopic Rockall score, Rockall score, AIMS65 score, shock index score, PRBC transfusion, the use of NSAIDs, antiplatelet drugs, or anticoagulants.
CONCLUSION:
Our study demonstrates that delayed EGD (after 24 hours), endoscopic therapy, the need for FFP transfusion, and acute kidney injury are associated with prolonged hospital stay. Coagulopathy requiring FFP transfusion and AKI reflects the severity of UGIB. Urgent EGD and endoscopic intervention in these patients may decrease the LOS and improve outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.